Rektumkarzinom: Aktueller Stand der multimodalen Therapie – wann und wie?

 

 Buy Article Permissions and Reprints

Zusammenfassung

Die neoadjuvante Langzeit-Radiochemotherapie (5-FU und 50,4 Gy) gefolgt von qualitätsgesicherter tiefer anteriorer Rektumresektion unter kompletter Mitnahme des Mesorektums (totale mesorektale Exzision, TME) stellt die Standardtherapie des lokal fortgeschrittenen Rektumkarzinoms (UICC II und III) des mittleren und unteren Rek­tumdrittels dar. Die neoadjuvante Radiochemotherapie ist der adjuvanten deutlich überlegen durch eine höhere R0-Resektionsrate und das deutlich niedrigere Rezidivrisiko. Diese neo­adju­vante multimodale Strategie hat das Lokal­rezi­div­risiko nach 5 und 10 Jahren auf unter 10 % gesenkt. Allerdings bleibt das Gesamtüberleben der Patienten davon unverändert und die Entwicklung von Lebermetastasen (35–45 %) ist ein nach wie vor ungelöstes Problem. Zusätzlich erhalten etwa 25 % der Patienten keine adjuvante Chemotherapie aufgrund chirurgischer Komplikationen oder mangelnder Compliance der Patienten. Die Integration von effektiven Chemotherapeutika in das multimodale Therapiekonzept stellt deswegen eine besondere Herausforderung dar. Mit der Erweiterung der therapeutischen Optionen bleibt allerdings die Frage zu klären, zu welchem Zeitpunkt und in welcher Dosierung / Dosisdichte Chemotherapeutika zukünftig appliziert werden sollen. Zur Vermeidung unnötiger, the­ra­pieassoziier­ter Toxizität und unter Gewährleistung maximaler Effektivität stellt die Identifizierung geeigneter Patienten für ein niedrig toxisches Standardregime gegenüber Patienten mit der Notwendigkeit einer intensivierten multimodalen Therapie anhand prädiktiver und prognostischer Biomarker die vielversprechendste Option zur zukünftigen individualisierten, rezidivadaptierten Therapie dar. Die Implementierung dieser aktuellen Entwicklungen in multizentrische Therapiestudien erfordert eine ganz besonders enge interdisziplinäre Zusammenarbeit von Strahlentherapeuten, Onkologen, Gastroenterologen, Pathologen und Chirurgen. 

Abstract

Preoperative 5-fluorouracil-based radiochemotherapy (RCT) followed by quality assessed total mesorectal excision (TME surgery) are the two most important elements of multimodal treatment for patients with locally advanced rectal cancer (UICC stages II and III). The optimum sequence of these neoadjuvant modalities complemented by adjuvant (postoperative) chemother­apy, has been addressed in several randomised trials. Especially within the trials of the German Rectal Cancer Study Group (GRCSG), preoperative RCT has been shown to be superior to postoperative treatment for a variety of endpoints (patho­log­ically confirmed complete tumour remission (pCR), RCT-induced tumour regression, R0 resection rates (including circumferential resection margins) and long-term locoregional control). This neoadjuvant multimodal strategy has decreased the 5-year and 10-year local recurrence rates below 10 %, and the development of distant metastases (e. g., 35 % to 45 % liver metastases) remains the predominant reason for failure. Furthermore, approximately 25 % of patients do not receive adjuvant chemotherapy, mainly due to surgical complications, patients’ refusal or the investigator’s discretion. Thus, today, integrating more effective systemic therapy into (preopera­tive) multimodal regimens is the most accepted challenge! But from the clinical point of view this demand is also a dilemma. The question to be addressed is how and when to apply intensified systemic therapy with adequate dosage and inten­sity as well as acceptable treatment-associated ­toxicity. The increase of therapeutic options requires valid predictive biomarkers that may help to stratify patients into regimens associated with low toxicity (5-FU monotherapy alone) or into more intensified treatment for better long-term outcome. In summary, the use of biomarkers for individualised risk-adapted treatment is one of the most promising areas of clinical investigations, not only in rectal cancer. The assessment of individual ­tumour response, toxi­city, and prognosis during multimodal treatment of rectal cancer as a model of a very common solid tumour offers radio­oncologists, surgeons, pathologists, gastro­enterologists as well as oncologists immense insights into the under­standing of tumour biology. 

Literatur

• 1 Heald R J, Husband E M, Ryall R D. The mesorectum in rectal cancer surgery – the clue to pelvic recurrence?.  Br J Surg. 1982;  69 613-616
  CrossrefPubMedGoogle Scholar
• 2 MacFarlane J K, Ryall R D, Heald R J. Mesorectal excision for rectal cancer.  Lancet. 1993;  341 457-460
  CrossrefPubMedGoogle Scholar
• 3 Havenga K, Enker W E, Norstein J et al. Improved survival and local control after total mesorectal excision or D3 lymphadenectomy in the treatment of primary rectal cancer: an international analysis of 1411 patients.  Eur J Surg Oncol. 1999;  25 368-374
  CrossrefPubMedGoogle Scholar
• 4 Kapiteijn E, Marijnen C A, Nagtegaal I D et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.  N Engl J Med. 2001;  345 638-646
  CrossrefPubMedGoogle Scholar
• 5 Sauer R, Becker H, Hohenberger W et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer.  NEJM. 2004;  17 1731-1740
  PubMedGoogle Scholar
• 6 Roh M S, Colangelo L H, O’Connell M J et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.  J Clin Oncol. 2009;  27 5124-5130
  CrossrefPubMedGoogle Scholar
• 7 Valentini V, Aristei C, Glimelius B et al. Multidisciplinary Rectal Cancer Management: 2^nd European Rectal Cancer Consensus Conference (EURECA-CC2).  Radiother Oncol. 2009;  92 148-163
  CrossrefPubMedGoogle Scholar
• 8 Rödel C, Arnold D, Liersch T. Rectal Cancer.. In: Blanke C D, et al. Hrsg Gastrointestinal Oncology – A Practical Guide.. Berlin Heidelberg: Sprin­ger; 2011: 379-422
  Google Scholar
• 9 Schmiegel W, Reinacher-Schick A et al. [Update S3-guideline “colorectal cancer” 2008].  Z Gastroenterol. 2008;  46 799-840
  Article in Thieme ConnectPubMedGoogle Scholar
• 10 Sauer R, Liersch T, Merkel S et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: Results of the German CAO / ARO / AIO-94 randomized phase III trial after a median follow up of 11 years. ASCO Annual Meeting, abstract 80285 2011
  Google Scholar
• 11 Gérard J P, Azria D, Gourgou-Bourgade S et al. Comparison of two neo­adjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12 / 0405-Prodige 2.  J Clin Oncol. 2010;  28 1638-1644
  CrossrefPubMedGoogle Scholar
• 12 Gerard J P, Conroy T, Bonnetain F et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3–4 rectal cancers: results of FFCD 9203.  J Clin Oncol. 2006;  24 4620-4625
  CrossrefPubMedGoogle Scholar
• 13 Bosset J F, Collette L, Calais G for the EORTC Radiotherapy Group Trial 22921 et al.,. Chemotherapy with preoperative radiotherapy in rectal cancer.  N Engl J Med. 2006;  355 1114-1123
  CrossrefPubMedGoogle Scholar
• 14 Augestad K M, Lindsetmo R O, Stulberg J et al. International preoperative rectal cancer management: Staging, neoadjuvant treatment, and impact of multidisciplinary teams.  World J Surg. 2010;  34 2689-2700
  CrossrefPubMedGoogle Scholar
• 15 Liersch T, Rothe H, Ghadimi B M et al. Therapie beim lokal fortgeschrittenen Rektumkarzinom – Ansätze zur Individualisierung.  Chirurg. 2009;  80 281-293
  CrossrefPubMedGoogle Scholar
• 16 Sebag-Montefiore D, Stephens R J, Steele R et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial.  Lancet. 2009;  373 811-820
  CrossrefPubMedGoogle Scholar
• 17 Peeters K C, Marijnen C A, Nagtegaal I D et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma.  Ann Surg. 2007;  246 693-701
  CrossrefPubMedGoogle Scholar
• 18 Bujko K, Nowacki M P, Nasierowska-Guttmejer A et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer.  Br J Surg. 2006;  93 1215-1223
  CrossrefPubMedGoogle Scholar
• 19 Bujko K, Nowacki M P, Nasierowska-Guttmejer A et al. Sphincter pre­servation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy.  Radiother Oncol. 2004;  72 15-24
  CrossrefPubMedGoogle Scholar
• 20 Soreide O, Norstein J, Fielding L P et al. International standardization and documentation of the treatment of rectal cancer.. In: Soreide O, Norstein J, Eds. Rectal cancer surgery. Optimisation – standardisation – documentation.. Berlin, Heidelberg, New York: Springer; 1997: 405-445
  Google Scholar
• 21 Sobin L H, Gospodarowicz M K, Wittekind D. UICC: TNM classification of malignant tumors.. 7 th edition Oxford: Wiley-Blackwell; 2009
  Google Scholar
• 22 Edge S B, Byrd D R, Compton C C et al. AJCC cancer staging manual.. 7th ed. New York: Springer; 2010
  Google Scholar
• 23 Vorwerk H, Liersch T, Rothe H et al. Gold markers for tumor localization and target volume delineation in radiotherapy for rectal cancer.  Strahlenther Onkol. 2009;  185 127-133
  CrossrefPubMedGoogle Scholar
• 24 Beets-Tan R G, Beets G L. Preoperative staging of rectal tumors: what is the most optimal staging method?.  Onkologie. 2008;  31 222-223
  CrossrefPubMedGoogle Scholar
• 25 MERCURY Study Group . Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study.  Radiology. 2007;  243 132-139
  CrossrefPubMedGoogle Scholar
• 26 Kim N K, Kim M J, Yun S H et al. Comparative study of transrectal ultrasonography, pelvic computerized tomography, and magnetic resonance imaging in preoperative staging of rectal cancer.  Dis Colon Rectum. 1999;  42 770-775
  CrossrefPubMedGoogle Scholar
• 27 Harewood G C, Wiersema M J, Nelson H et al. A prospective, blinded assessment of the impact of preoperative staging on the management of rectal cancer.  Gastroenterology. 2002;  123 24-32
  CrossrefPubMedGoogle Scholar
• 28 Kulinna C, Scheidler J, Strauss T et al. Local staging of rectal cancer: assessment with double-contrast multislice computed tomography and transrectal ultrasound.  J Comput Assist Tomogr. 2004;  28 123-130
  CrossrefPubMedGoogle Scholar
• 29 Taylor A, Slater A, Mapstone N et al. Staging rectal cancer: MRI com­pared to MDCT.  Abdom Imaging. 2007;  32 323-327
  CrossrefPubMedGoogle Scholar
• 30 Vliegen R, Dresen R, Beets G et al. The accuracy of Multi-detector row CT for the assessment of tumor invasion of the mesorectal fascia in primary rectal cancer.  Abdom Imaging. 2008;  33 604-610
  CrossrefPubMedGoogle Scholar
• 31 M.E.R.C.U.R.Y. Project (Magnetic Resonance Imaging and Rectal Cancer European Equivalence Study) .2002 Study Protocol. (Study Coordinator I. Daniels, FRCS, Pelican Centre, North Hampshire Hospital, Basingstoke, Hampshire, UK) http://http://www.pelicancancer.org/researchprojects
  Google Scholar
• 32 Barbaro B, Fiorucci C, Tebala C et al. Locally advanced rectal cancer: MR imaging in prediction of response after preoperative chemotherapy and radiation therapy.  Radiology. 2009;  250 730-739
  CrossrefPubMedGoogle Scholar
• 33 Lahaye M J, Engelen S M, Kessels A G et al. USPIO-enhanced MR imaging for nodal staging in patients with primary rectal cancer: predictive criteria.  Radiology. 2008;  246 804-811
  CrossrefPubMedGoogle Scholar
• 34 Chowdhury F U, Shah N, Scarsbrook A F et al. [¹⁸F]FDG PET/CT imaging of colorectal cancer: a pictorial review.  Postgrad Med J. 2010;  86 174-182
  CrossrefPubMedGoogle Scholar
• 35 Hillner B E, Siegel B A, Shields A F et al. The impact of positron emission tomography (PET) on expected management during cancer treatment: findings of the National Oncologic PET Registry.  Cancer. 2009;  115 410-418
  CrossrefPubMedGoogle Scholar
• 36 Weber W A, Figlin R. Monitoring cancer treatment with PET / CT: does it make a difference?.  J Nucl Med. 2007;  48 36S-44S
  PubMedGoogle Scholar
• 37 Wahl R L, Jacene H, Kasamon Y et al. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.  J Nucl Med. 2009;  50 122S-150S
  CrossrefPubMedGoogle Scholar
• 38 Bosset J F, Calais G, Mineur L et al. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: prelimi­nary results – EORTC 22921.  J Clin Oncol. 2005;  23 5620-5627
  CrossrefPubMedGoogle Scholar
• 39 Bosset J F, Collette L, Calais G et al. Chemotherapy with preoperative radiotherapy in rectal cancer.  N Engl J Med. 2006;  355 1114-1123
  CrossrefPubMedGoogle Scholar
• 40 Frykholm G J, Pahlman L, Glimelius B. Combined chemo- and radiotherapy vs. radiotherapy alone in the treatment of primary, nonresectable adenocarcinoma of the rectum.  Int J Radiat Oncol Biol Phys. 2001;  50 427-434
  CrossrefPubMedGoogle Scholar
• 41 Arbman G, Nilsson E, Hallbook O et al. Local recurrence following total mesorectal excision for rectal cancer.  Br J Surg. 1996;  83 375-379
  CrossrefPubMedGoogle Scholar
• 42 Dahlberg M, Glimelius B, Pahlman L. Changing strategy for rectal cancer is associated with improved outcome.  Br J Surg. 1999;  86 379-384
  CrossrefPubMedGoogle Scholar
• 43 Wibe A, Moller B, Norstein J et al. A national strategic change in treatment policy for rectal cancer – implementation of total mesorectal excision as routine treatment in Norway. A national audit.  Dis Colon Rectum. 2002;  45 857-866
  CrossrefPubMedGoogle Scholar
• 44 Porter G A, Soskolne C L, Yakimets W W et al. Surgeon-related factors and outcome in rectal cancer.  Ann Surg. 1998;  227 157-167
  CrossrefPubMedGoogle Scholar
• 45 Hermanek P, Hohenberger W, Klimpfinger M et al. The pathological assessment of mesorectal excision: implications for further treatment and quality management.  Int J Colorectal Dis. 2003;  18 335-341
  PubMedGoogle Scholar
• 46 Stockholm Rectal Cancer Study Group . Preoperative short-term radiation therapy in operable rectal carcinoma. A prospective randomized trial.  Cancer. 1990;  66 49-55
  CrossrefPubMedGoogle Scholar
• 47 Stockholm Colorectal Cancer Study Group . Randomized study on preoperative radiotherapy in rectal carcinoma.  Ann Surg Oncol. 1996;  3 423-430
  CrossrefPubMedGoogle Scholar
• 48 Swedish Rectal Cancer Trial . Improved survival with preoperative radiotherapy in resectable rectal cancer.  N Engl J Med. 1997;  336 980-987
  CrossrefPubMedGoogle Scholar
• 49 Pahlman L, Glimelius B. Pre- or postoperative radiotherapy in rectal and rectosigmoid carcinoma. Report from a randomized multicenter trial.  Ann Surg. 1990;  211 187-195
  CrossrefPubMedGoogle Scholar
• 50 Peeters K C, Marijnen C A, Nagtegaal I D et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma.  Ann Surg. 2007;  246 693-701
  CrossrefPubMedGoogle Scholar
• 51 Marijnen C A, Nagtegaal I D, Klein Kranenbarg E et al. No downstaging after short-term preoperative radiotherapy in rectal cancer patients.  J Clin Oncol. 2001;  19 1976-1984
  PubMedGoogle Scholar
• 52 Rodel C, Martus P, Papadoupolos T et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.  J Clin Oncol. 2005;  23 8688-8696
  CrossrefPubMedGoogle Scholar
• 53 Maas M, Nelemans P J, Valentini V et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data.  Lancet Oncol. 2010;  11 835-844
  CrossrefPubMedGoogle Scholar
• 54 Capirci C, Valentini V, Cionini L et al. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients.  Int J Radiat Oncol Biol Phys. 2008;  72 99-107
  CrossrefPubMedGoogle Scholar
• 55 Rodel C, Grabenbauer G G, Papadopoulos T et al. Phase I / II trial of capecitabine, oxaliplatin, and radiation for rectal cancer.  J Clin Oncol. 2003;  21 3098-3104
  CrossrefPubMedGoogle Scholar
• 56 Rodel C, Liersch T, Hermann R M et al. Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer.  J Clin Oncol. 2007;  25 110-117
  PubMedGoogle Scholar
• 57 Hofheinz R D, von Gerstenberg-Helldorf B, Wenz F et al. Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer.  J Clin Oncol. 2005;  23 1350-1357
  CrossrefPubMedGoogle Scholar
• 58 Rodel C, Arnold D, Hipp M et al. Phase I–II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer.  Int J Radiat Oncol Biol Phys. 2008;  70 1081-1086
  CrossrefPubMedGoogle Scholar
• 59 Horisberger K, Treschl A, Mai S et al. Cetuximab in combination with ­capecitabine, irinotecan, and radiotherapy for patients with locally ­advanced rectal cancer: results of a Phase II MARGIT trial.  Int J Radiat Oncol Biol Phys. 2009;  74 1487-1493
  CrossrefPubMedGoogle Scholar
• 60 Bertolini F, Chiara S, Bengala C et al. Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer.  Int J Radiat Oncol Biol Phys. 2009;  73 466-472
  CrossrefPubMedGoogle Scholar
• 61 Debucquoy A, Haustermans K, Daemen A et al. Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer.  J Clin Oncol. 2009;  27 2751-2757
  CrossrefPubMedGoogle Scholar
• 62 Weiss C, Arnold D, Dellas K et al. Preoperative radiotherapy of advanced rectal cancer with capecitabine and oxaliplatin with or without cetuximab: A pooled analysis of three prospective phase I–II trials.  Int J Radiat Oncol Biol Phys. 2010;  78 472-478
  CrossrefPubMedGoogle Scholar
• 63 Roedel C, Becker H, Fietkau R et al. Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: First results of the German CAO / ARO / AIO-04 randomized phase III trial. ASCO Annual Meeting 2011, abstract 78728 2011
  Google Scholar
• 64 Kundel Y, Brenner R, Purim O et al. Is local excision after complete pathological response to neoadjuvant chemoradiation for rectal cancer an acceptable treatment option?.  Dis Colon Rectum. 2010;  53 1624-1631
  CrossrefPubMedGoogle Scholar
• 65 Habr-Gama A, Perez R O, Wynn G et al. Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization.  Dis Colon Rectum. 2010;  53 1692-1698
  CrossrefPubMedGoogle Scholar
• 66 Hiotis S P, Weber S M, Cohen A M et al. Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients.  J Am Coll Surg. 2002;  194 131-135 discussion 135-136
  CrossrefPubMedGoogle Scholar
• 67 Sprenger T, Rothe H, Jung K et al. Stage II / III rectal cancer with intermediate response to preoperative radiochemotherapy: do we have indications for individual risk stratification?.  World J Surg Oncol. 2010;  8 27
  CrossrefPubMedGoogle Scholar
• 68 Sprenger T, Rothe H, Langer C et al. Preoperative chemoradiotherapy does not necessarily reduce lymph node retrieval in rectal cancer specimens--results from a prospective evaluation with extensive pathological work-up.  J Gastrointest Surg. 2010;  14 96-103
  CrossrefPubMedGoogle Scholar
• 69 Habr-Gama A, Perez R O, Nadalin W et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.  Ann Surg. 2004;  240 711-717 discussion 717-718
  PubMedGoogle Scholar
• 70 Habr-Gama A. Assessment and management of the complete clinical response of rectal cancer to chemoradiotherapy.  Colorectal Dis. 2006;  8 21-24
  CrossrefPubMedGoogle Scholar
• 71 Habr-Gama A, Perez R O, Sabbaga J et al. Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period.  Dis Colon Rectum. 2009;  52 1927-1934
  CrossrefPubMedGoogle Scholar
• 72 Yeo S G, Kim D Y, Kim T H et al. Pathologic complete response of primary tumor following preoperative chemoradiotherapy for locally advanced rectal cancer: long-term outcomes and prognostic significance of pathologic nodal status (KROG 09-01).  Ann Surg. 2010;  252 998-1004
  CrossrefPubMedGoogle Scholar
• 73 Collette L, Bosset J F, den Dulk M et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group.  J Clin Oncol. 2007;  25 4379-4386
  CrossrefPubMedGoogle Scholar
• 74 Collette L et al. Correspondence.  J Clin Oncol. 2008;  26 508-509
  CrossrefPubMedGoogle Scholar
• 75 Cionini L et al. Final results of a randomized trial on adjuvant chemotherapy after preoperative chemoradiation in rectal cancer.  Radiother Oncol. 2010;  96 Abstract 299 Comment on: Capirci C, Valentini V, Cionini L, De Paoli A, Rodel C, Glynne-Jones R, Coco C, Romano M, Mantello G, Palazzi S, Mattia FO, Friso ML, Genovesi D, Vidali C, Gambacorta MA, Buffoli A, Lupattelli M, Favretto MS, La Torre G. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys 2008; 72: 99-107
  PubMedGoogle Scholar
• 76 Bujko K, Glynne-Jones R, Bujko M. Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials.  Ann Oncol. 2010;  21 1743-1750
  CrossrefPubMedGoogle Scholar
• 77 Rectal cancer V.2. NCCN Clinical Practical Guidelines in Oncology 2010 http://http://www.nccn.org/professionals/physician_gls/PDF/rectal.pdf
  Google Scholar
• 78 Glimelius B, Oliveira J. Rectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.  Ann Oncol. 2009;  20 54-56
  PubMedGoogle Scholar
• 79 Francois Y, Nemoz C J, Baulieux J et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial.  J Clin Oncol. 1999;  17 2396
  PubMedGoogle Scholar
• 80 Veenhof A A, Kropman R H, Engel A F et al. Preoperative radiation therapy for locally advanced rectal cancer: a comparison between two different time intervals to surgery.  Int J Colorectal Dis. 2007;  22 507-513
  CrossrefPubMedGoogle Scholar
• 81 Tulchinsky H, Shmueli E, Figer A et al. An interval > 7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer.  Ann Surg Oncol. 2008;  15 2661-2667
  CrossrefPubMedGoogle Scholar
• 82 De Campos-Lobato L F, Geisler D P, da Luz Moreira A et al. Neoadjuvant therapy for rectal cancer: The impact of longer interval between chemoradiation and surgery.  J Gastrointest Surg. 2011;  15 444-450
  CrossrefPubMedGoogle Scholar
• 83 Moore H G, Gittleman A E, Minsky B D et al. Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection.  Dis Colon Rectum. 2004;  47 279-286
  CrossrefPubMedGoogle Scholar
• 84 Dolinsky C M, Mahmoud N N, Mick R et al. Effect of time interval between surgery and preoperative chemoradiotherapy with 5-fluoro­uracil or 5-fluorouracil and oxaliplatin on outcomes in rectal cancer.  J Surg Oncol. 2007;  96 207-212
  CrossrefPubMedGoogle Scholar
• 85 Lim S B, Choi H S, Jeong S Y et al. Optimal surgery time after preoperative chemoradiotherapy for locally advanced rectal cancers.  Ann Surg. 2008;  248 243-251
  CrossrefPubMedGoogle Scholar
• 86 Kalady M F, de Campos-Lobato L F, Stocchi L et al. Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer.  Ann Surg. 2009;  250 582-589
  PubMedGoogle Scholar
• 87 Garcia-Aguilar J, Smith D D, Avila K Timing of Rectal Cancer Response to Chemoradiation Consortium et al., on behalf of the. Optimal timing of surgery after chemoradiation for advanced rectal cancer: Preliminary results of a multicenter, nonrandomized phase II prospective trial.  Ann Surg. 2011;  254 97-102
  CrossrefPubMedGoogle Scholar
• 88 Habr-Gama A, Perez R O, Sabbaga J et al. Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period.  Dis Colon Rectum. 2009;  52 1927-1934
  CrossrefPubMedGoogle Scholar
• 89 Fernandez-Martos C, Pericay C, Aparicio J et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus Oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study.  J Clin Oncol. 2010;  28 859-865
  CrossrefPubMedGoogle Scholar
• 90 Ghadimi B M, Grade M, Difilippantonio M J et al. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy.  J Clin Oncol. 2005;  23 1826-1838
  CrossrefPubMedGoogle Scholar
• 91 Liersch T, Grade M, Gaedcke J et al. Preoperative chemoradiotherapy in locally advanced rectal cancer: correlation of a gene expression-based response signature with recurrence.  Cancer Genet Cytogenet. 2009;  190 57-65
  CrossrefPubMedGoogle Scholar
• 92 Ghadimi B M, Grade M. Cancer gene profiling for response prediction.  Methods Mol Biol. 2010;  576 327-339
  PubMedGoogle Scholar
• 93 Grade M, Hummon A B, Camps J et al. A genomic strategy for the functional validation of colorectal cancer genes identifies potential therapeutic targets.  Int J Cancer. 2011;  128 1069-1079
  CrossrefPubMedGoogle Scholar
• 94 Liersch T, Gaedcke J, Grade M et al. Molekulare Marker zur Responseprädiktion beim lokal fortgeschrittenen Rektumkarzinom. Kommt die Individualisierung der Therapie?.  Der Onkologe. 2010;  16 779-788
  CrossrefPubMedGoogle Scholar
• 95 Grade M, Gaedcke J, Wangsa D et al. Chromosomal copy number changes of locally advanced rectal cancers treated with preoperative chemoradiotherapy.  Cancer Genet Cytogenet. 2009;  193 19-28
  CrossrefPubMedGoogle Scholar
• 96 Grade M, Ghadimi B M, Varma S et al. A massive aneuploidy-dependent massive deregulation of the cellular transcriptome and apparent divergence of the Wnt / beta-catenin signaling pathway in human rectal carcinomas.  Cancer Res. 2006;  66 267-282
  CrossrefPubMedGoogle Scholar
• 97 Gaedcke J, Grade M, Jung K et al. KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy.  Radiother Oncol. 2010;  94 76-81
  CrossrefPubMedGoogle Scholar
• 98 Gaedcke J Grade M, Jung K et al. Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas.  Genes Chromosomes Cancer. 2010;  49 1024-1034
  CrossrefPubMedGoogle Scholar
• 99 Conradi L C, Bleckmann A, Schirmer M et al. Thymidylate Synthase as a Prognostic Biomarker for Locally Advanced Rectal Cancer after multimodal Treatment.  Ann Surg Oncol. 2011;  [Epub ahead of print]
  PubMedGoogle Scholar
• 100 Sprenger T Rödel F, Beissbarth T et al. Failure of down-regulation of Survivin following neoadjuvant radiochemotherapy in rectal cancer is associated with distant metastases and shortened survival.  Clin Cancer Res. 2011;  17 1623-1631
  CrossrefPubMedGoogle Scholar
• 101 Sobin L H, Wittekind C. TNM classification of malignant tumors.. Berlin: Springer; 2002
  Google Scholar
• 102 Merkel S, Mansmann U, Papadopoulos T et al. The prognostic inhomogeneity of colorectal carcinomas Stage III: a proposal for subdivision of Stage III.  Cancer. 2001;  92 2754-2759
  CrossrefPubMedGoogle Scholar
• 103 Merkel S, Mansmann U, Siassi M et al. The prognostic inhomogeneity in pT3 rectal carcinomas.  Int J Colorectal Dis. 2001;  16 298-304
  CrossrefPubMedGoogle Scholar
• 104 Chan A K, Wong A, Jenken D et al. Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy.  Int J Radiat Oncol Biol Phys. 2005;  61 665-677
  CrossrefPubMedGoogle Scholar
• 105 Quah H M, Chou J F, Gonen M et al. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation.  Cancer. 2008;  113 57-64
  CrossrefPubMedGoogle Scholar
• 106 Fietkau R, Barten M, Klautke G et al. Postoperative chemotherapy may not be necessary for patients with ypN0-category after neoadjuvant chemoradiotherapy of rectal cancer.  Dis Colon Rectum. 2006;  49 1284-1292
  CrossrefPubMedGoogle Scholar

1 gleichberechtigte Erstautoren

Prof. Dr. B. M. Ghadimi

Universitätsmedizin Göttingen · Allgemein- und Viszeralchirurgie

Robert-Koch-Str. 40

37075 Göttingen

Deutschland

Phone: 05 51 / 39 87 00

Fax: 05 51 / 39 87 00

Email: mghadim@uni-goettingen.de

• Supplementary Material